Owlstone MedicalOwlstone Medical develops non-invasive diagnostics for cancer, inflammatory disease and infectious disease. The company developed a breathalyzer for disease detection. Their Breath Biopsy platform is used to discover novel non-invasive biomarkers in breath which could transition to point-of-care. The ReCIVA Breath Sampler collects breath samples and analyzes volatile organic compounds (VOCs) using the microchip chemical senor technology, FAIMS (High Field Asymmetric waveform Ion Mobility Spectrometry), which detects biomarkers of disease.
Owlstone is developing tests for lung cancer, colorectal cancer and asthma stratification by therapeutic response. The company also offers Breath Biopsy products and services to academic, clinical and pharma partners looking to develop breath based diagnostics for their own applications.
Owlstone Medical is developing a breathalyzer for disease with a focus on non-invasive diagnostics for the early detection of disease and on precision medicine, initially targeting lung cancer, liver disease, digestive health, and respiratory disease, to achieve the company’s mission to save 100,000 lives.
The Company’s Breath Biopsy® platform includes ReCIVA®, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial Breath Biopsy Laboratory located in Cambridge, U.K. with support through an office in Research Triangle Park, NC, USA, and the development of the world’s largest Digital Breath Biobank matched to patient phenotype.